AU2022405443A1 - Methods for treating diseases using malt1 inhibitors - Google Patents

Methods for treating diseases using malt1 inhibitors Download PDF

Info

Publication number
AU2022405443A1
AU2022405443A1 AU2022405443A AU2022405443A AU2022405443A1 AU 2022405443 A1 AU2022405443 A1 AU 2022405443A1 AU 2022405443 A AU2022405443 A AU 2022405443A AU 2022405443 A AU2022405443 A AU 2022405443A AU 2022405443 A1 AU2022405443 A1 AU 2022405443A1
Authority
AU
Australia
Prior art keywords
malt1 inhibitor
subject
malt1
administered
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022405443A
Other languages
English (en)
Inventor
Subhabrata Biswas
Barbara Saxton Fox
Andrew John LONG
Dania Mounir RABAH
Patricia Elaine RAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rarefied Biosciences Inc
Original Assignee
Rarified Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rarified Biosciences Inc filed Critical Rarified Biosciences Inc
Publication of AU2022405443A1 publication Critical patent/AU2022405443A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022405443A 2021-12-10 2022-12-09 Methods for treating diseases using malt1 inhibitors Pending AU2022405443A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202163288085P 2021-12-10 2021-12-10
US202163288081P 2021-12-10 2021-12-10
US202163288083P 2021-12-10 2021-12-10
US63/288,085 2021-12-10
US63/288,081 2021-12-10
US63/288,083 2021-12-10
US202263306655P 2022-02-04 2022-02-04
US202263306660P 2022-02-04 2022-02-04
US202263306657P 2022-02-04 2022-02-04
US63/306,660 2022-02-04
US63/306,657 2022-02-04
US63/306,655 2022-02-04
PCT/US2022/052450 WO2023107721A1 (en) 2021-12-10 2022-12-09 Methods for treating diseases using malt1 inhibitors

Publications (1)

Publication Number Publication Date
AU2022405443A1 true AU2022405443A1 (en) 2024-05-30

Family

ID=86731143

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022405443A Pending AU2022405443A1 (en) 2021-12-10 2022-12-09 Methods for treating diseases using malt1 inhibitors

Country Status (6)

Country Link
US (1) US20250032493A1 (https=)
EP (1) EP4444340A4 (https=)
JP (1) JP2024546121A (https=)
AU (1) AU2022405443A1 (https=)
CA (1) CA3240140A1 (https=)
WO (1) WO2023107721A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121419973A (zh) * 2023-06-30 2026-01-27 詹森药业有限公司 Malt1抑制剂
WO2025082417A1 (zh) * 2023-10-18 2025-04-24 苏州沙砾生物科技有限公司 一种表达融合蛋白的细胞及其应用
WO2025223516A1 (zh) * 2024-04-24 2025-10-30 首药控股(北京)股份有限公司 一种抑制剂杂环化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201903280T4 (tr) * 2011-08-02 2019-04-22 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Malt1 proteazının fenotiazin türevleri ile selektif inhibisyonu.
EA201590916A1 (ru) * 2012-11-09 2016-02-29 Корнэлл Юниверсити Низкомолекулярные ингибиторы malt1
AU2016352813B2 (en) * 2015-11-13 2019-09-19 Novartis Ag Novel pyrazolo pyrimidine derivatives
IL294214B2 (en) * 2019-12-27 2026-04-01 Schrodinger Inc Cyclic compounds and methods for using them
WO2021207343A1 (en) * 2020-04-08 2021-10-14 Rheos Medicines, Inc. Malt1 inhibitors and uses thereof

Also Published As

Publication number Publication date
JP2024546121A (ja) 2024-12-17
US20250032493A1 (en) 2025-01-30
WO2023107721A1 (en) 2023-06-15
CA3240140A1 (en) 2023-06-15
EP4444340A1 (en) 2024-10-16
EP4444340A4 (en) 2025-12-24

Similar Documents

Publication Publication Date Title
EP4444340A1 (en) Methods for treating diseases using malt1 inhibitors
Ito et al. A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model
EP1778224B1 (en) Flt3 inhibitors for immune suppression
Bechtel Pruritus in pregnancy and its management
CN105228453B (zh) 用于治疗与炎症相关的疾病的去乙基羟氯喹
UA119767C2 (uk) Лікування b-клітинних злоякісних новоутворень із застосуванням комбінації інгібіторів jak та pi3k
CN104039325A (zh) 布鲁顿酪氨酸激酶(btk)抑制剂的用途
Mitchell et al. LILRA5 is expressed by synovial tissue macrophages in rheumatoid arthritis, selectively induces pro‐inflammatory cytokines and IL‐10 and is regulated by TNF‐α, IL‐10 and IFN‐γ
EP4313023A1 (en) Combination treatment methods of multiple sclerosis
Biswas et al. Pharmacological inhibition of MALT1 ameliorates autoimmune pathogenesis and can be uncoupled from effects on regulatory T-cells
WO2017007405A1 (en) Methods and compounds for the alleviation and/or prevention of bone loss
US20260041685A1 (en) Methods of treating indolent systemic mastocytosis
JP2019502739A (ja) レイノー現象および免疫異常を患う患者における全身性強皮症の予防治療に使用するためのｐ２ｙ１２受容体を阻害する物質
TW201204360A (en) Treatment of multiple sclerosis with MASITINIB
CN118715019A (zh) 用于使用malt1抑制剂治疗疾病的方法
WO2012078504A1 (en) TREATMENT OF CHRONIC INFLAMMATION WITH A 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVE
Tsuji Pathogenesis and Treatment of Interstitial Lung Disease Accompanied by Anti-melanoma Differentiation-associated Gene 5-positive Idiopathic Inflammatory Myopathies
WO2014191822A1 (en) BENZOIC ACID DERIVATIVES AS IL-15Rα RECEPTOR INHIBITORS
Goldman et al. Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease
TW202432117A (zh) 用於治療全身性硬化症之可溶性鳥苷酸環化酶活化劑
RU2749731C2 (ru) Применение ингибиторов активности или функции pi3k для лечения первичного синдрома шегрена
EP4643863A1 (en) Pharmaceutical composition and use thereof
WO2014191823A1 (en) Amine derivatives as il-15 activity inhibitors
William et al. SB1578, a Novel Inhibitor of JAK2, FLT3
CN111587120A (zh) 免疫原性组合物及其用途